Schedule H1 Antibiotics Compliance in India: What Pharmacists and Manufacturers Need to Know

Schedule H1 is a prescription-only category under the Drugs and Cosmetics Rules, 1945, carrying stricter requirements than standard Schedule H. It was introduced to address antibiotic overuse and misuse, and has since been extended to controlled analgesics, sedatives, and anti-tuberculosis drugs.

This guide covers the Schedule H1 requirements, the original 2013 gazette and subsequent amendments, the full drug list, and the most recent changes in 2026 - including the addition of Pregabalin and the proposed (not yet enacted) additions under a draft gazette.

What Schedule H1 Actually Requires

Schedule H1 imposes three requirements beyond standard Schedule H:

1. NRx label in red: Every Schedule H1 product must display the symbol "NRx" in red on its label (not just "Rx"). The label must also include the warning: "Warning: It is dangerous to take this preparation except under medical supervision."
2. Separate dispensing register: Every pharmacy dispensing a Schedule H1 drug must maintain a separate register recording each dispensing. The register must capture: drug name and strength; quantity dispensed; prescription date; patient name and age; prescribing doctor's name and Medical Council registration number.
3. Three-year register retention: The dispensing register must be retained for a minimum of 3 years and must be available for inspection by Drug Inspectors.

Origin of Schedule H1: G.S.R. 588(E), 30 August 2013

Schedule H1 was introduced by G.S.R. 588(E), dated 30 August 2013, which amended the Drugs and Cosmetics Rules, 1945. The schedule came into force on 1 March 2014 - a six-month transition period was allowed for labelling compliance.

The original 2013 notification included 46 drugs. These included the third- and fourth-generation cephalosporins (Ceftriaxone, Ceftazidime, Cefepime, Cefixime, Cefoperazone and others), all carbapenems available at the time (Imipenem, Meropenem, Doripenem, Ertapenem, Faropenem), fluoroquinolones (Levofloxacin, Moxifloxacin, Gemifloxacin), anti-tuberculosis drugs, opioids, benzodiazepines, sedatives, and antivirals (Oseltamivir, Zanamivir).

The current confirmed list contains 51 entries (the original 46 plus subsequent additions including Tapentadol, Oseltamivir, Zanamivir, Oxytocin, and Pregabalin pending full transition).

2026 Amendments to Schedule H1

1. Pregabalin Added - G.S.R. 377(E), 13 May 2026

Pregabalin was added to Schedule H1 by G.S.R. 377(E), dated 13 May 2026. This follows increasing regulatory concern about Pregabalin misuse - the drug has been reported as a substance of abuse, particularly in certain states, and has been found in combination with opioids in overdose cases.

The gazette includes a 180-day transition period for labelling compliance. This means full H1 compliance - including NRx labelling and the separate dispensing register - becomes mandatory approximately in November 2026.

2. Draft Additions - G.S.R. 745(E), 19 August 2026 (Not Yet in Force)

The Ministry of Health published a draft gazette notification G.S.R. 745(E) on 19 August 2026, proposing to add four further drugs to Schedule H1:

• Flupentixol (an antipsychotic)
• Zopiclone (a sleep medication - non-benzodiazepine hypnotic)
• Gabapentin (an anticonvulsant/neuropathic pain drug)
• Carisoprodol (a muscle relaxant)

The rationale for these additions reflects abuse and misuse concerns: Gabapentin and Pregabalin are both under closer scrutiny globally; Carisoprodol (combined with codeine) has been flagged in overdose reports; Zopiclone misuse has been documented; Flupentixol at low doses is being used as an anxiolytic-antidepressant in primary care with limited oversight.

Why Schedule H1 Was Created: The Antibiotic Stewardship Context

India accounts for a substantial share of global antibiotic consumption, and both inappropriate prescribing and OTC dispensing of antibiotics have been documented as significant contributors to antimicrobial resistance (AMR). A 2014 LANCET study noted India as one of the world's largest consumers of antibiotics per capita.

The Schedule H1 classification of carbapenems, third- and fourth-generation cephalosporins, and fluoroquinolones was intended to:

• Prevent OTC dispensing of broad-spectrum and reserve antibiotics
• Create a dispensing record that can be audited by Drug Inspectors
• Signal to prescribers and dispensers that these are restricted agents requiring specific justification

Enforcement remains inconsistent - compliance with H1 register requirements, particularly for oral formulations like Cefixime and Levofloxacin at retail pharmacies, is not universal. However, the legal requirement is clear and carries penalties under the Drugs and Cosmetics Act for non-compliance.

Schedule H1 and the WHO AWaRe Framework

WHO's AWaRe classification - Access, Watch, Reserve - is a global tool for antibiotic stewardship. The drugs in Schedule H1 map significantly to the Watch and Reserve categories:

India's NLEM 2022 incorporates AWaRe classification for antibiotics. Schedule H1 is India's regulatory mechanism for restricting access to these higher-tier antibiotics - it is functionally equivalent to what many countries call "restricted antibiotic" dispensing.

Compliance Failures: What Drug Inspectors Look For

Drug Inspector inspections of pharmacies specifically check for Schedule H1 compliance. Common violations found:

• No separate H1 register (separate from the general prescription/poison register)
• H1 register missing required fields (doctor's Medical Council registration number is frequently absent)
• H1 register entries not made at the time of dispensing
• Dispensing of Schedule H1 antibiotics without a prescription
• Products in stock lacking the NRx symbol (older stock is permitted; new stock must comply)

Penalties for non-compliance with Schedule H1 dispensing requirements are under the Drugs and Cosmetics Act - including cancellation or suspension of retail drug licence for repeat violations.

This article is based on publicly available gazette notifications as of October 2026. Schedule H1 is amended periodically. Verify the current list and any transition period deadlines against the official gazette before making compliance decisions. This article is for informational purposes and does not constitute legal advice.